Romosozumab and Cardiovascular Safety: Bridging the Gap between Clinical Trials and Real-World Evidence
Beom-Jun Kim · 2026
Read Romosozumab and Cardiovascular Safety: Bridging the Gap between Clinical Trials and Real-World Evidence by Beom-Jun Kim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13341178.txt.
Description
Heart safety questions around the osteoporosis drug romosozumab are weighed by Beom-Jun Kim in a 2026 review. The antibody blocks sclerostin, building bone while slowing its breakdown, and produces fast density gains and fewer fractures in severe postmenopausal osteoporosis.
Trial results conflict: FRAME against placebo looked reassuring, while ARCH against alendronate showed more major cardiovascular events in the first year, prompting boxed warnings. Kim asks whether the signal reflects true heart toxicity or a protective effect of the comparator drug. Lab and tissue studies have not found a convincing mechanism for harm, leaving real-world evidence to help settle the question.
Catalog record
| CREATOR | Beom-Jun Kim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 7336 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |